Search

Atrasentan

Atrasentan is a novel, selective endothelin A receptor antagonist (SERA). … [L52855] In April 2025, atrasentan was granted accelerated approval by the FDA for the reduction of proteinuria in patients with primary IgA nephropathy, becoming the first endothelin A receptor antagonist

Sulfinpyrazone

A uricosuric drug that is used to reduce the serum urate levels in gout therapy. It lacks anti-inflammatory, analgesic, and diuretic properties.

Omidenepag isopropyl

The use of an EP2 receptor agonist such as omidenepag represents an alternative in these scenarios. Omidenepag IOP-lowering effect is comparable to the one observed with [latanoprost]. … Omidenepag isopropyl is a topical ocular hypotensive agent used to reduce intraocular pressure (IOP) in patients with glaucoma and ocular hypertension.

Olsalazine

Olsalazine is an aminosalicylate and a prodrug of [mesalamine] (5-aminosalicylic acid, 5-ASA). … [A257078] Olsalazine comprises two mesalamine molecules joined by an azo bridge, which is cleaved in the colon.

Binimetinib

detected by an FDA-approved test. … Binimetinib, also known as _Mektovi_, is a potent and selective oral mitogen-activated protein kinase 1/2 (MEK 1/2) inhibitor which is combined with [Encorafenib].

Hydrolyzed soy protein

Fospropofol

Fospropofol is a water soluble prodrug and is converted to propofol in the liver. Fospropofol is a short acting hypnotic/sedative/anesthetic agent. … Fospropofol is a Schedule IV controlled substance in the United States under the Controlled Substances Act.

Betibeglogene autotemcel

donor due to the risks of graft rejection, graft-versus-host disease, and other treatment-related toxic effects. … [L42940] β-thalassemia is a condition caused by mutations in the β-globin gene (HBB) that leads to a significant decrease in the production of β-globin.

Tranilast

It has been used for the treatment of allergic disorders such as asthma, allergic rhinitis and atopic dermatitis. … Tranilast is an antiallergic drug developed by Kissei Pharmaceuticals. In 1982, it was approved in Japan and South Korea for the management of bronchial asthma.

Delorazepam

It may have adverse effects such as drowsiness, and cognitive impairments such as short term memory impairment. Delorazepam is an active metabolite of the benzodiazepine known as cloxazolam. … It is a long acting benzodiazepine which makes it superior in this sense to lorazepam which is short acting. Lorazepam is also a major active metabolite of delorazepam.